Genentech, a member of the Roche Group (RHHBY), announced positive results from the Phase III evERA study evaluating investigational giredestrant in combination with everolimus in people with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer previously treated with a cyclin-dependent kinase 4/6 inhibitor and endocrine therapy. The study met both co-primary endpoints, showing a statistically significant and clinically meaningful improvement in progression-free survival in both the intention-to-treat and ESR1-mutated populations, compared with standard-of-care endocrine therapy plus everolimus.
Levi Garraway, chief medical officer and head of Global Product Development, said: "We look forward to discussing these results with regulatory authorities with the goal of making this giredestrant-based regimen available to many people with advanced ER-positive breast cancer."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.